AN-2690, a novel antifungal for the topical treatment of onychomycosis.
Schering-Plough Corp, under license from Anacor Pharmaceuticals Inc, is developing AN-2690, an antifungal agent with activity against Trichophyton species, in a topical solution formulation, for the potential treatment of onychomycosis. Phase II and IIb trials with AN-2690 are underway.